Uncategorized
Glaukos Submits IND Application to FDA to Study iDoseTM Travoprost Intraocular Implant in Glaucoma Patients
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its Travoprost Intraocular Implant with the iDoseTM delivery system for investigation
